Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GigaGen Seeks Partners For Antibody Pipelines Against 17 IO Targets

Executive Summary

Using its proprietary Surge platform, GigaGen is able to capture and interrogate natural immune systems rapidly and identify every antibody in circulation against virtually any cancer target. Speaking to Scrip at the Biotech Showcase, CEO David Johnson said he was now seeking partners for 17 distinct IO targets, including common checkpoint inhibitors PD-1 and CTLA-4, and more novel targets such as TIM-3 and VISTA.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts